StockNews.com Begins Coverage on Senseonics (NYSE:SENS)

Research analysts at StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Trading Up 2.4 %

NYSE:SENS opened at $0.36 on Tuesday. The company has a quick ratio of 2.89, a current ratio of 3.11 and a debt-to-equity ratio of 59.17. Senseonics has a 1-year low of $0.32 and a 1-year high of $0.75. The firm has a market capitalization of $192.39 million, a price-to-earnings ratio of -2.59 and a beta of 0.79. The stock has a fifty day simple moving average of $0.38 and a 200 day simple moving average of $0.42.

Senseonics (NYSE:SENS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. The firm had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.86 million. Sell-side analysts forecast that Senseonics will post -0.13 earnings per share for the current year.

Institutional Trading of Senseonics

Several institutional investors have recently bought and sold shares of SENS. Virtu Financial LLC acquired a new stake in Senseonics in the 1st quarter valued at $162,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Senseonics by 30.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after purchasing an additional 211,128 shares in the last quarter. State Board of Administration of Florida Retirement System acquired a new position in Senseonics in the first quarter worth $91,000. Vanguard Group Inc. boosted its stake in Senseonics by 0.7% in the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after purchasing an additional 155,715 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its stake in Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares in the last quarter. Institutional investors and hedge funds own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.